CERE
Cerevel Therapeutics Holdings, Inc.
41.25
USD
This page is just a preview of the data found in TrendSpider’s full version
Cerevel Therapeutics Holdings, Inc. stock is up 72.23% since 30 days ago. The next earnings date is Feb 21, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 62.5% of the previous 11 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 10 CALLs. 0% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 07 Dec 20:58 | 19 Jan, 2024 | 35.00 | 1763 | ||
| 07 Dec 20:59 | 19 Jan, 2024 | 35.00 | 1763 | ||
| 08 Dec 18:18 | 19 Jan, 2024 | 25.00 | 2110 | ||
| 08 Dec 18:18 | 19 Jan, 2024 | 25.00 | 2110 | ||
| 08 Dec 18:18 | 19 Jan, 2024 | 25.00 | 2110 | ||
| 08 Dec 18:18 | 19 Jan, 2024 | 25.00 | 2110 | ||
| 08 Dec 18:19 | 19 Jan, 2024 | 25.00 | 2110 | ||
| 08 Dec 20:28 | 15 Dec, 2023 | 30.00 | 752 | ||
| 08 Dec 20:31 | 15 Dec, 2023 | 30.00 | 752 | ||
| 08 Dec 20:31 | 15 Dec, 2023 | 30.00 | 752 |
Cerevel Therapeutics Holdings, Inc. engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist, and CVL-871, which is in Phase 2a clinical trial to treat dementia-related apathy.
